UBS Group
EVMN

UBS Group’s Evommune Inc EVMN Stock Holding History

UBS Group’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.5M Buy
413,553
+115,178
+39% +$2.68M ﹤0.01% 4074
2026
Q1 		$6.86M Buy
298,375
+294,961
+8,640% +$6.67M ﹤0.01% 3742
2025
Q4 		$58.4K Buy
+3,414
New +$64.1K ﹤0.01% 7146

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

UBS Group's EVMN Position: Q2 2026 in Review

UBS Group increased its Evommune Inc (EVMN) stake by 39% in Q2 2026, buying an estimated $2.68M and bringing the position to 413,553 shares worth $5.5M. The position accounts for ﹤0.01% of the portfolio, ranked #4074.

UBS Group first reported a position in EVMN in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.86M in Q1 2026. 105 funds tracked by Wall St. Rank hold EVMN as of Q2 2026.

  • UBS Group held 413,553 shares of Evommune Inc worth $5.5M as of Q2 2026.
  • UBS Group bought 115,178 Evommune Inc shares in Q2 2026, an estimated $2.68M.
  • Evommune Inc made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4074 holding.
  • UBS Group first reported a position in Evommune Inc in Q4 2025 and has held it in 3 quarters since.
  • UBS Group's Evommune Inc position peaked at $6.86M in Q1 2026.
  • 105 funds tracked by Wall St. Rank held Evommune Inc as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.